Home

Metagenomi, Inc. - Common Stock (MGX)

2.8500
0.00 (0.00%)

Metagenomi, Inc. is a biotechnology company focused on the advancement of gene editing technologies for therapeutic applications

With a strong emphasis on leveraging its proprietary genomic tools, the company aims to develop novel treatments for genetic disorders and other complex diseases. Metagenomi's innovative approach combines advanced bioengineering and synthetic biology to create precision therapies that can effectively address a wide range of medical challenges. Through rigorous research and collaboration with leading scientific institutions, Metagenomi is dedicated to transforming the landscape of gene therapy and improving patient outcomes.

SummaryNewsPress ReleasesChartHistoricalFAQ
Stargate, Netflix, GE Aerospace, Twilio, and Morefool.com
There's a lot for investors to talk about.
Via The Motley Fool · January 29, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 22, 2025
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 22, 2025
Expert Outlook: Metagenomi Through The Eyes Of 4 Analystsbenzinga.com
Via Benzinga · December 10, 2024
Peeling Back The Layers: Exploring Metagenomi Through Analyst Insightsbenzinga.com
Via Benzinga · September 6, 2024
Unveiling 4 Analyst Insights On Metagenomibenzinga.com
Via Benzinga · August 21, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 9, 2024
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Mondaycogent-com
Via Benzinga · August 19, 2024
MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024investorplace.com
MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024investorplace.com
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 14, 2024
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soarsbenzinga.com
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.
Via Benzinga · May 2, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · May 2, 2024
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaireinvestorplace.com
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.
Via InvestorPlace · May 2, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · April 19, 2024
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yetfool.com
A bumpy start can't detract from this company's strong balance sheet.
Via The Motley Fool · February 19, 2024
Gilead-Backed Kyverna Overshoots Raised IPO Expectationstalkmarkets.com
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
Via Talk Markets · February 11, 2024